NCT05366322 is a clinical trial in SARS-CoV-2, sponsored by ModernaTX, Inc..

Who is sponsoring NCT05366322?

NCT05366322 is sponsored by ModernaTX, Inc..

What condition does NCT05366322 study?

NCT05366322 studies SARS-CoV-2.

Is NCT05366322 still recruiting?

NCT05366322 is currently completed. Last updated 9 May 2022.

Last reviewed 2022-05-09 · How we verify

NCT05366322

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Study to Compare mRNA-1273 Versus BNT162b2 COVID-19 Vaccines Among Immunocompromised Adults

Completed Last updated 9 May 2022

What this trial tests

trial in SARS-CoV-2 in 124,879 participants. Completed in 21 March 2022.

Timeline

10 September 2021

Primary endpoint
4 February 2022

21 March 2022

Quick facts

Lead sponsor	ModernaTX, Inc.
Status	Completed
Study type	OBSERVATIONAL
Enrollment	124,879
Start date	10 September 2021
Primary completion	4 February 2022
Estimated completion	21 March 2022
Sites	1 location across United States

Conditions studied

SARS-CoV-2 — all drugs for SARS-CoV-2 →

Sponsor

ModernaTX, Inc. — full company profile →

Who can join

18 and older, any sex, with SARS-CoV-2. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The goal of this study is to compare real-world effectiveness of the mRNA-1273 vaccine versus the BNT162b2 vaccine on medically attended COVID-19 and COVID-19 hospitalizations among fully vaccinated immunocompromise participants.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Real-world comparative effectiveness of mRNA-1273 and BNT162b2 vaccines among immunocompromised adults identified in administrative claims data in the United States.
Mues KE, Kirk B, Patel DA, Gelman A, et al · · 2022 · cited 17× · PMID 36163093 · DOI 10.1016/j.vaccine.2022.09.025
mRNA-Based Vaccine for COVID-19: They Are New but Not Unknown!
Chavda VP, Jogi G, Dave S, Patel BM, et al · · 2023 · cited 15× · PMID 36992091 · DOI 10.3390/vaccines11030507
Real-world comparative effectiveness of mRNA-1273 and BNT162b2 vaccines among immunocompromised adults in the United States
Mues KE, Kirk B, Patel DA, Gelman A, et al · · 2022 · cited 1× · DOI 10.1101/2022.05.13.22274960

Verify or expand the search:

Other recruiting trials for SARS-CoV-2

Currently open trials in the same condition.

NCT07266558 — A Study to Evaluate the Efficacy and Safety of mRNA-1283 and mRNA-1273 in Participants 50 to 64 Years of Age Without Hig · Phase 4 · recruiting
NCT06684379 — Study on Safety and Efficacy of Two Doses of PRS CK STORM in the Modulation of the Cytokine Storm for the Treatment of A · Phase 1, PHASE2 · recruiting
NCT06585241 — A Study to Investigate the Immunogenicity and Safety of mRNA COVID-19 Variant-containing Vaccine Formulations · Phase 4 · recruiting
NCT05876377 — Use and Effectiveness of COVID-19 Vaccines Using State Vaccine Registries and Insurance Claims Data · active not recruiting
NCT05799651 — Safety and Immunogenicity of Glycovax-002 Vaccine in Healthy Adults · Phase 1 · active not recruiting

Other ModernaTX, Inc. trials

Trials by the same sponsor.

NCT07496450 — A Study of mRNA-1018-H5 Pandemic Influenza Vaccine in Healthy Adults · Phase 3 · recruiting
NCT07478952 — A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189 in Healthy Adults 18 to 30 Years of Age · Phase 1 · recruiting
NCT07266558 — A Study to Evaluate the Efficacy and Safety of mRNA-1283 and mRNA-1273 in Participants 50 to 64 Years of Age Without Hig · Phase 4 · recruiting
NCT07116616 — A Study of mRNA-2808 in Participants With Relapsed or Refractory Multiple Myeloma · Phase 1, PHASE2 · recruiting
NCT07117487 — A Study of mRNA-1345 Following a Primary Dose of a Licensed Protein Subunit Respiratory Syncytial Virus (RSV) Vaccine in · Phase 3 · active not recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05366322 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by ModernaTX, Inc.
Last refreshed: 9 May 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05366322.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing